New safety check for RSV protection in vulnerable babies
NCT ID NCT06851806
Summary
This study is checking the safety of a medicine called palivizumab that helps prevent severe RSV lung infections in high-risk children. It involves 138 Indian infants and toddlers under 2 years old who were born very early, have chronic lung disease, or have serious heart conditions. Children receive monthly injections for up to 5 months while researchers monitor for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGHyderabad, 500084, India
-
Research Site
NOT_YET_RECRUITINGPune, 411006, India
Conditions
Explore the condition pages connected to this study.